top of page
Our Commercial and Development Pipeline is Focused on Serving the
Unmet Medical Needs of Patients Across a Range of Therapeutic Areas
Therapeutic Development Pipeline
Aeterna is regaining rights to macimorelin (Macrilen™) in the United States and Canada in May 2023 and is engaged in robust business development efforts to identify and secure a new development and commercialization partner in these territories.
bottom of page